FDA Publishes Generic-Drug User Fees - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Publishes Generic-Drug User Fees


FDA has published the required generic-drug user fees for fiscal year  (FY) 2014. The fees are required under the Generic Drug User Fee Amendments of 2012 (GDUFA).

FDA minimized the increase in fees due to the continued adjustment of the industry to the new requirements. Included in the FY 2014 fees is an increase over the 2013 fees. Total revenue for the first year of the program in 2013 included a one-time fee for applications pending as of October 1, 2012.  This one time fee has been removed and the remaining fees make up the total revenue, which resulted in the increase. Additional factors were used to calculate the facility fee including the number of facilities that self-identify under GDUFA.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here